ICER, CADTH, and NICE collaborate to increase transparency in health technology evaluations
The Institute for Clinical and Economic Review (ICER), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the UK’s National Institute for Health and Care Excellence (NICE) have announced changes to the way confidential information about health technologies is handled. The aim is to streamline processes and increase transparency while balancing the need to protect confidential information. The three organizations have been working together to create a more consistent approach to handling clinical data. ICER has updated its academic-in-confidence data policy, reducing the period during which data is redacted from external and public documents from 18 months to 12 months. These changes will come into effect in May 2023.
Recent Posts
Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft Annual Work Programm...
How will the EU Health Technology Assessment framework evolve in 2026 to improve clinical evaluations for cancer treatments and advanced therapies? The EU Health Technology Assessment (HTA) initiative coordinates standardized reviews of medicines and devices across Member States, thereby boosting...
WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults
What does the latest WHO guideline reveal about GLP-1 obesity therapies, as released in December 2025? This landmark document establishes the first global standards for integrating glucagon-like peptide-1 (GLP-1) receptor agonists and GIP/GLP-1 dual agonists into chronic obesity management, treat...
Strengthening EU Pharmaceutical Supply Security Through the Critical Medicines Act
Enhancing EU Supply Security for Essential Pharmaceuticals
The EU's Critical Medicines Act proposal is a key initiative to strengthen EU pharmaceutical supply security amid ongoing shortages of vital drugs like antibiotics,...